Table 1B. Hazards ratios of ASPN and BCR; for ASPN mRNA in Mortensen et al, and ASPN H-score in the McGill TMA. Cox analysis of ASPN H-score in the complete McGill TMA.

		Univariate analysis					Multivariate analysis
	N (n)	HR	95% CI	P-value	P-valuea	P-valueb	HR	95% CI	P-value
ASPN	302 (78)	2.16	1.21–3.85	0.009	0.013	0.063	1.77	0.97–3.22	0.062
Age	294 (78)	1.02	0.98–1.06	0.411	0.411	1.000	0.99	0.95–1.03	0.638
Gleason score	302 (78)	23.59	3.28–169.7	0.002	0.004	0.014	16.70	2.28–122.2	0.006
Stage	302 (78)	3.11	1.98–4.88	7.76E−07	5.40E−06	5.40E−06	1.77	1.06–2.98	0.030
PSA	302 (78)	1.03	1.00–1.05	0.015	0.018	0.105	1.00	0.97–1.02	0.808
SM	302 (78)	2.11	1.34–3.03	0.001	0.002	0.007	1.25	0.76–2.06	0.383
SV	302 (78)	3.57	1.88–6.79	1.04E−04	3.64E−04	7.28E−04	1.98	0.98–4.00	7.44E−05

Abbreviations: ASPN=asporin; BCR=biochemical recurrence; CI=confidence interval; FDR=false discovery rate; HR=hazards ratio; PSA=prostate specific antigen; SM=surgical margin; SV=seminal vesicle; TMA=tissue microarray.

Cox proportional hazards ratio of ASPN H-score in the McGill TMA cohort. Univariate and multivariate Cox analysis of ASPN staining and clinical variables in McGill cohort. ASPN H-score of >150 showed a hazards ratio of 2.16 (P=0.009) in univariate and 1.77 (P=0.062) in multivariate analysis.

^aFDR-adjusted P-value.

^bBonferroni adjusted P-value. Bold indicates statistically significant values.